Theorem Clinical Research

Drug Sponsors

Vertex cuts workforce 15%

Wednesday, October 30, 2013 11:12 AM

Global biotech Vertex Pharmaceuticals will focus its investment on future opportunities in cystic fibrosis and other high-potential R&D programs and is reducing its workforce related to the support of INCIVEK, because of the continued and rapid decline in the number of people being treated with INCIVEK as other new medicines for hepatitis C near approval.

More... »


Regeneron, BioMed Realty break ground on New York R&D facility

Monday, October 28, 2013 02:36 PM

Regeneron Pharmaceuticals and BioMed Realty Trust have broken ground on a new 300,000-square-foot build-to-suit research facility for Regeneron at BioMed Realty's The Landmark at Eastview campus in Westchester County, New York.

More... »


McKesson to acquire Celesio for $8.3 billion

Monday, October 28, 2013 02:34 PM

McKesson, a North American healthcare services and information technology company, has signed an agreement to acquire a majority stake in Celesio, an international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors, for $32 per share and to launch parallel voluntary public tender offers for the remaining publicly-traded shares and outstanding convertible bonds of Celesio. The offer price represents a 39% premium over the three-month volume weighted average price prior to the market speculation that began Oct. 8. The total transaction, including the assumption of Celesio’s outstanding debt, is valued at approximately $8.3 billion.

More... »

Increasing affluence, legislative reforms are transforming Poland’s pharmaceutical market

Monday, October 28, 2013 02:22 PM

Decision Resources has found that Poland’s increasing affluence—as well as its reforms and policy initiatives on healthcare quality, access, privatization and financing—have contributed to growth in the country’s pharmaceutical market during the last decade.

More... »

Illumina to acquire NextBio

Monday, October 28, 2013 02:20 PM

Illumina, a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function based in San Diego, will acquire Santa Clara-based NextBio, a provider of clinical and genomic informatics.

More... »

AstraZeneca proposes closing Brixham Environmental Laboratory

Friday, October 25, 2013 11:45 AM

AstraZeneca has announced proposals to close its Environmental Laboratory in Brixham, Devon, U.K. The laboratory, with 71 staff members, provides specialist services to assess the impact of pharmaceuticals and chemicals used by a range of industries on the environment.

More... »

SRI International completes R&D facility expansion

Friday, October 25, 2013 11:43 AM

SRI International has completed the final stage of expansion of its 40,000-square-foot R&D facility in Harrisonburg, Va. SRI funded the $2.8 million build-out to further advance its bioscience research capabilities at SRI's Shenandoah Valley (SRI SV) Center for Advanced Drug Research.

More... »

Amarin to eliminate 50% of staff following FDA Advisory Committee vote

Wednesday, October 23, 2013 03:13 PM

Amarin, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, plans to reduce operating expenses by eliminating approximately 50% of its staff worldwide, following the recent recommendation of the FDA Endocrinologic and Metabolic Drugs Advisory Committee against the potential Vascepa (icosapent ethyl) label expansion.

More... »

Amgen acquires Filgrastim franchise rights from Roche in 100 markets

Wednesday, October 23, 2013 02:45 PM

Amgen has entered into a definitive agreement with F. Hoffmann-La Roche (Roche) to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective January 2014.

More... »

Sideris Pharmaceuticals inks agreement with Novartis

Wednesday, October 23, 2013 02:27 PM

Sideris Pharmaceuticals has entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive right to acquire Sideris and its lead asset, the iron-chelating candidate SP-420. Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $300 million.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs